Guixue Hou

Dr. Guixue Hou

orcid

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 October 2020 in Nature Communications
Verified
Journal Article
Open access
PDF file
YZYifei Zhang
Yifei Zhang
YGYanyun Gu
Yanyun Gu
HRHuahui Ren
Huahui Ren
SWShujie Wang
Shujie Wang
HZHuanzi Zhong
Huanzi Zhong
WWWeiqing Wang
Weiqing Wang
Human gut microbiome is a promising target for managing type 2 diabetes (T2D). Measures altering gut microbiota like oral intake of probiotics or berberine (BBR), a bacteriostatic agent, merit metabolic homoeostasis. We hence conducted a randomized, double-blind, placebo-controlled trial with newly diagnosed T2D patients from 20 centres in China. Four-hundred-nine eligible participants were enroled, randomly assigned (1:1:1:1) and completed a 12-week treatment of either BBR-alone, probiotics+BBR, probiotics-alone, or placebo, after a one-week run-in of gentamycin pretreatment. The changes in glycated haemoglobin, as the primary outcome, in the probiotics+BBR (least-squares mean [95% CI], −1.04[−1.19, −0.89]%) and BBR-alone group (−0.99[−1.16, −0.83]%) were significantly greater than that in the placebo and probiotics-alone groups (−0.59[−0.75, −0.44]%, −0.53[−0.68, −0.37]%, P < 0.001). BBR treatment induced more gastrointestinal side effects. Further metagenomics and metabolomic studies found that the hypoglycaemic effect of BBR is mediated by the inhibition of DCA biotransformation by Ruminococcus bromii. Therefore, our study reports a human microbial related mechanism underlying the antidiabetic effect of BBR on T2D. (Clinicaltrial.gov Identifier: NCT02861261).

16 October 2020 in Nature Communications
Verified
Journal Article
Open access
PDF file
YXYue Xuan
Yue Xuan
NBNicholas W. Bateman
Nicholas W. Bateman
SGSebastien Gallien
Sebastien Gallien
SGSandra Goetze
Sandra Goetze
YZYue Zhou
Yue Zhou
Thomas ConradsThomas Conrads
Thomas Conrads
Cancer has no borders: Generation and analysis of molecular data across multiple centers worldwide is necessary to gain statistically significant clinical insights for the benefit of patients. Here we conceived and standardized a proteotype data generation and analysis workflow enabling distributed data generation and evaluated the quantitative data generated across laboratories of the international Cancer Moonshot consortium. Using harmonized mass spectrometry (MS) instrument platforms and standardized data acquisition procedures, we demonstrate robust, sensitive, and reproducible data generation across eleven international sites on seven consecutive days in a 24/7 operation mode. The data presented from the high-resolution MS1-based quantitative data-independent acquisition (HRMS1-DIA) workflow shows that coordinated proteotype data acquisition is feasible from clinical specimens using such standardized strategies. This work paves the way for the distributed multi-omic digitization of large clinical specimen cohorts across multiple sites as a prerequisite for turning molecular precision medicine into reality.

13 November 2024 in Cell Death & Differentiation
Verified
Journal Article
Closed access
PDF file
HLHao Liu
Hao Liu
SZShanliang Zheng
Shanliang Zheng
GHGuixue Hou
Guixue Hou
JDJunren Dai
Junren Dai
YZYanan Zhao
Yanan Zhao
YHYing Hu
Ying Hu

8 January 2026 in Science
Verified
Journal Article
Closed access
JYJianhua Yin
Jianhua Yin
YZYuhui Zheng
Yuhui Zheng
ZHZhuoli Huang
Zhuoli Huang
WZWenwen Zhou
Wenwen Zhou
YYYue Yuan
Yue Yuan
CLChuanyu Liu
Chuanyu Liu
Human peripheral blood exhibits molecular and cellular heterogeneity across populations, yet the underlying mechanisms remain unclear. We present the Chinese Immune Multi-Omics Atlas (CIMA), characterizing molecular variations linked to sex, age, and genetic variants through multi-omics analysis of more than 10 million circulating immune cells from 428 Chinese adults. CIMA established an enhancer-driven gene regulatory network comprising 237 robust regulons; identified 9600 eGenes and 52,361 caPeaks at cell type resolution; and revealed pleiotropic associations among immune-related disease risk loci, cis-expression quantitative trait loci (QTLs), and chromatin accessibility QTLs. Furthermore, the cell language model CIMA-CLM predicted chromatin accessibility and evaluated the effects of noncoding variants from chromatin sequences and gene expression. CIMA provides a comprehensive reference for immune-related disease research.

1 June 2023 in Journal of Clinical Investigation
Verified
Journal Article
Open access
PDF file
QLQingyu Lin
Qingyu Lin
TLTong Liu
Tong Liu
XWXingwen Wang
Xingwen Wang
GHGuixue Hou
Guixue Hou
ZXZhiyuan Xiang
Zhiyuan Xiang
YHYing Hu
Ying Hu
Programmed cell death ligand 1 (PD-L1) is an immune checkpoint protein frequently expressed in human cancers that contributes to immune evasion through its binding to PD-1 on activated T cells. Unveiling the mechanisms underlying PD-L1 expression is essential for understanding the impact of the immunosuppressive microenvironment and is also crucial for the purpose of reboosting antitumor immunity. However, how PD-L1 is regulated, particularly at translational levels, remains largely unknown. Here, we discovered that a long noncoding RNA (lncRNA), HIF-1α inhibitor at translation level (HITT), was transactivated by E2F transcription factor 1 (E2F1) under IFN-γ stimulation. It coordinated with regulator of G protein signaling 2 (RGS2) in binding to the 5′ UTR of PD-L1, resulting in reduced PD-L1 translation. HITT expression enhanced T cell–mediated cytotoxicity both in vitro and in vivo in a PD-L1–dependent manner. The clinical correlation between HITT/PD-L1 and RGS2/PD-L1 expression was also detected in breast cancer tissues. Together, these findings demonstrate the role of HITT in antitumor T cell immunity, highlighting activation of HITT as a potential therapeutic strategy for enhancing cancer immunotherapy.

17 October 2022 in BJOG: An International Journal of Obstetrics & Gynaecology
Verified
Journal Article
Closed access
GHGuixue Hou
Guixue Hou
YGYa Gao
Ya Gao
LPLiona C. Poon
Liona C. Poon
YRYan Ren
Yan Ren
CZChunwei Zeng
Chunwei Zeng
KNKypros Herodotos Nicolaides
Kypros Herodotos Nicolaides